Product Overview
Zyvex Pharmaceuticals lists Ibutamoren as one hundred tablets of 25 mg, and the label carries the code that made it famous: MK 677. The compound is an orally active, non-peptide agonist at the ghrelin receptor, which means it imitates the hunger hormone rather than supplying growth hormone. The pituitary answers with its own release, and IGF-1 in circulation stays raised for up to twenty-four hours after a dose.
That mechanism is worth stating plainly because the product is sold in the company of SARMs and behaves nothing like one. It does not touch the androgen receptor, does not suppress natural testosterone, and does not convert to estrogen. What it does do is change appetite, sleep and fluid balance, and those three effects are what most users actually notice.
The clinical base is thin. A small study of fourteen participants found that 25 mg before sleep increased the proportion of REM sleep, and the drug has an investigational status with no approval for human consumption anywhere. The half-life measured in animals is four to six hours, which is short, yet the downstream IGF-1 response is what stretches the dosing interval to a single daily tablet. Where this product sits in a plan, it sits beside the SARM line rather than on top of it: the oral stack cards such as Ligandrol LGD 4033 and Ostarine MK 2866 describe recovery and lean mass, while this tablet describes hormone output.
Dosage Protocol
The reference figures below come from research and user convention, and no approved dose exists.
| Level | Amount | Length | Note |
| Beginner | 10-15 mg daily | 8-12 weeks | Starts low and is taken in the evening |
| Intermediate | 25 mg daily | 8-12 weeks | The amount used in the small clinical sleep study |
| Advanced | 25 mg daily | Up to 12-16 weeks | Data above 25 mg a day are limited, so the ceiling is not a target |
| Female | Not confirmed | - | No separate female protocol appears in the sources |
| Route | Oral tablet | Once daily | Before sleep suits the natural overnight pulse of growth hormone |
Timing is the only lever worth adjusting. Growth hormone is released in pulses, and the largest of them arrives after sleep begins, so an evening tablet lands on top of that window. Anyone who takes it in the morning tends to notice the appetite effect during the day instead and the sleep effect not at all.
Suggested Protocols
Nothing here is a tested combination. The pairings are catalogue arrangements, and the logic of each one is stated so the user can judge whether it holds for them.
What to Expect
- Growth hormone and IGF-1 rise, and the IGF-1 response is still measurable a day after the tablet, which is why one dose a day is enough.
- Sleep is the effect with published support: 25 mg before bed raised REM sleep in a small study of young and older participants.
- Appetite usually increases, and this is described mostly in user reports rather than in clinical papers, so the size of the effect varies.
- Lean mass rose in trial work while overall fat mass did not change, which is a modest picture rather than a dramatic one.
- Cortisol is documented to rise, which matters to anyone juggling stress, sleep quality and recovery at the same time.
- Because the compound is not an androgen, no libido boost or shut down is expected, and none of the steroid recovery logic applies.
Side Effects and Management
Cycle Support: Why There Is No PCT Here
This is the section that separates the tablet from the rest of the shelf. Ibutamoren does not act on the androgen receptor and does not suppress natural testosterone production the way a steroid or a SARM does, so there is no shutdown for a SERM to correct and no reason to reach for Nolvadex Tamoxifen or Clomid Clomiphene afterwards. Inventing a recovery protocol here would be theatre.
